-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Bojian Company today announced that Fampridine Sustained-Release Tablets have been officially approved by the National Medical Products Administration for improving the walking ability of adult patients with multiple sclerosis and walking disorders (EDSS score 4-7)
.
Fampridine sustained-release tablets are the first approved treatment in China to improve the walking ability of adult MS patients
.
"Thanks to the National
Medical Products Administration for approving Fampridine Sustained Release Tablets through the priority review and approval process.
This is Bojian 's second MS treatment drug approved in China this year .
" said Wen Haoji, President of Bojian Asia Pacific.
Fampridine sustained-release tablets is the first therapeutic drug that can improve the walking ability of adult patients with MS and has proven its clinical efficacy in adult patients with MS
.
In May 2018, MS was included in the "First List of Rare Diseases"
.
MS is a lifelong and progressive autoimmune disease that affects the central nervous system.
The involvement of the central nervous system gradually causes physical disabilities and impairs neurological functions such as motor, vision, and cognition
"Multiple sclerosis is currently the main cause of non-traumatic neurological disability in young adults worldwide.
Almost all patients with multiple sclerosis will eventually experience varying degrees of walking disorder
.
This clinical outcome will greatly affect the independence of patients.
, Not only restricts their ability to work, but also causes a heavy mental burden on patients, and has a serious negative impact on their personal and family
In December 2020, the "2020 Comprehensive Social Survey Report on Patients with Multiple Sclerosis in China" released by the China Rare Diseases Alliance showed that nearly 90% of MS patients who are in a dropout or unemployed state are caused by the disease
.
Fampridine sustained-release tablets is the second MS treatment approved by Bojian in the Chinese market
.
In April 2021, Bojian drug dimethyl fumarate enteric-coated capsules were approved by the National Medical Products Administration of China for the treatment of relapsing multiple sclerosis
.
